Us Bancorp \De\ Enanta Pharmaceuticals Inc Transaction History

Us Bancorp \De\

$74.1 Billion
Q1 2025

A detailed history of Us Bancorp \De\ transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Us Bancorp \De\ holds 6,500 shares of ENTA stock, worth $35,360. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,500

Holding current value

$35,360

% of portfolio

0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	BUY	$4.82 - $8.49 $31,330 - $55,185	6,500 New	6,500 $35,000
Q3 2024 Oct 28, 2024	BUY	$10.05 - $16.54 $42,642 - $70,179	4,243 Added 4933.72%	4,329 $44,000
Q2 2024 Aug 06, 2024	SELL	$11.43 - $17.02 $9,509 - $14,160	-832 Reduced 90.63%	86 $1,000
Q1 2024 May 07, 2024	SELL	$10.08 - $17.46 $32,951 - $57,076	-3,269 Reduced 78.07%	918 $16,000
Q4 2023 Feb 09, 2024	BUY	$8.18 - $10.78 $26,691 - $35,175	3,263 Added 353.14%	4,187 $39,000
Q3 2023 Nov 03, 2023	BUY	$11.09 - $22.13 $8,872 - $17,704	800 Added 645.16%	924 $10,000
Q2 2023 Aug 09, 2023	SELL	$20.68 - $39.85 $4,963 - $9,564	-240 Reduced 65.93%	124 $2,000
Q1 2023 May 09, 2023	SELL	$38.82 - $54.59 $271 - $382	-7 Reduced 1.89%	364 $14,000
Q4 2022 Feb 13, 2023	SELL	$40.77 - $53.73 $774 - $1,020	-19 Reduced 4.87%	371 $17,000
Q3 2022 Oct 27, 2022	BUY	$48.29 - $71.27 $2,221 - $3,278	46 Added 13.37%	390 $20,000
Q2 2022 Aug 01, 2022	BUY	$38.13 - $76.93 $6,024 - $12,154	158 Added 84.95%	344 $16,000
Q1 2022 May 11, 2022	BUY	$56.06 - $74.11 $616 - $815	11 Added 6.29%	186 $13,000
Q4 2021 Feb 11, 2022	BUY	$60.19 - $97.37 $1,625 - $2,628	27 Added 18.24%	175 $13,000
Q3 2021 Nov 10, 2021	SELL	$41.02 - $58.65 $35,646 - $50,966	-869 Reduced 85.45%	148 $8,000
Q2 2021 Aug 05, 2021	SELL	$43.76 - $53.11 $7,351 - $8,922	-168 Reduced 14.18%	1,017 $45,000
Q1 2021 Apr 28, 2021	BUY	$41.69 - $54.95 $8,671 - $11,429	208 Added 21.29%	1,185 $58,000
Q4 2020 Feb 04, 2021	BUY	$41.16 - $47.47 $33,710 - $38,877	819 Added 518.35%	977 $41,000
Q3 2020 Nov 10, 2020	BUY	$43.36 - $53.53 $997 - $1,231	23 Added 17.04%	158 $7,000
Q2 2020 Aug 07, 2020	SELL	$46.37 - $57.58 $4,034 - $5,009	-87 Reduced 39.19%	135 $7,000
Q2 2019 Aug 13, 2019	SELL	$81.3 - $97.35 $2,439 - $2,920	-30 Reduced 11.9%	222 $19,000
Q1 2019 May 08, 2019	BUY	$69.08 - $105.66 $2,072 - $3,169	30 Added 13.51%	252 $24,000
Q4 2018 Feb 13, 2019	SELL	$65.41 - $84.65 $6,083 - $7,872	-93 Reduced 29.52%	222 $16,000
Q3 2018 Nov 01, 2018	SELL	$85.46 - $126.37 $2,051 - $3,032	-24 Reduced 7.08%	315 $27,000
Q3 2017 Nov 13, 2017	BUY	$37.91 - $46.8 $12,851 - $15,865	339	339 $16,000

Others Institutions Holding ENTA

# of Institutions

113

Shares Held

19.7M

Call Options Held

9.7K

Put Options Held

12.4K

Krensavage Asset Management, LLC New York, NY

2.12M
Shares

$11.5 Million
7.2% of portfolio
Farallon Capital Management LLC San Francisco, CA

2.11M
Shares

$11.5 Million
0.06% of portfolio
Vanguard Group Inc Valley Forge, PA

2.01M
Shares

$10.9 Million
0.0% of portfolio
Black Rock Inc. New York, NY

1.85M
Shares

$10.1 Million
0.0% of portfolio
Morgan Stanley New York, NY

1.22M
Shares

$6.65 Million
0.0% of portfolio

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $113M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account